<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108576</url>
  </required_header>
  <id_info>
    <org_study_id>MHBS-026-01</org_study_id>
    <nct_id>NCT00108576</nct_id>
  </id_info>
  <brief_title>Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)</brief_title>
  <official_title>Divalproex Sodium in the Treatment of PTSD: A Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:&#xD;
&#xD;
        -  To study the efficacy of divalproex in the treatment of PTSD;&#xD;
&#xD;
        -  To study the plasma GABA (gamma aminobutyric acid) levels before and after treatment&#xD;
           with divalproex in PTSD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To study the efficacy of divalproex in the treatment of PTSD. Research Design:&#xD;
      This is an 8-week randomized, double-blind, placebo-controlled treatment trial of divalproex.&#xD;
&#xD;
      Methodology: After signing an informed consent and meeting all inclusion/exclusion criteria,&#xD;
      the patient is randomized to either divalproex or placebo for an 8-week duration. During the&#xD;
      study a pharmacist maintains the randomization log and administers the placebo or divalproex&#xD;
      (500 mg/capsule) in look-a-like tablets. Patients' symptoms, side effects and compliance are&#xD;
      assessed bi-weekly. Based on symptomology and occurrence of side effects, the investigator&#xD;
      increases the medication in 500 mg (one tablet) increments every four days, as tolerated,&#xD;
      until a maximum therapeutic benefit is achieved, not to exceed 3000 mg/day (6 capsules). The&#xD;
      dosing is twice daily, with the higher dose at bedtime. Compliance is assessed by bi-weekly&#xD;
      pill count and blinded valproic acid levels at week 4 and week 8. Patients are given&#xD;
      supportive clinical management during the clinic visits. An investigator is available by&#xD;
      telephone 24 hrs a day in case of emergency. Patients may be seen more often if needed.&#xD;
      Efficacy will be measured by the following assessment scales: MADRS (Montgomery-Asberg&#xD;
      Depression Rating Scale), Ham-A (Hamilton Anxiety Scale), CGI-s (Clinical Global&#xD;
      Impressions-Severity of Illness Scale), CGI-I (Clinical Global Impressions-Improvement&#xD;
      Scale), GAF (Global Assessment of Functioning), CAPS (Clinician-Administered PTSD Scale),&#xD;
      TOP-8 (Treatment Outcome PTSD Rating Scale), and DTS (Davidson Trauma Scale). Results of this&#xD;
      study will be used to evaluate the efficacy of divalproex in the treatment of PTSD.&#xD;
&#xD;
      Significance: Divalproex has shown promise in treating PTSD in open label trials. This study&#xD;
      is the next step in proving divalproex's efficacy in the treatment of PTSD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale (CAPS)</measure>
    <time_frame>8weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Look-a-like placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Divalproex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex</intervention_name>
    <description>anticonvulsant; mood stabilizer</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Look-a-like placebo</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PTSD, confirmed by MINI (Mini-International Neuropsychiatric Interview)&#xD;
             and CAPS&#xD;
&#xD;
          -  Age 19 or older&#xD;
&#xD;
          -  No substance abuse/dependence for the previous 6 weeks (except for nicotine and&#xD;
             caffeine)&#xD;
&#xD;
          -  Free of psychotropic medication for 2 weeks (except 6 weeks for fluoxetine)&#xD;
&#xD;
          -  Clinically normal physical and laboratory examination (lab profile listed below). LFTs&#xD;
             (liver function tests) up to 2.5 times the normal limit will be allowed.&#xD;
&#xD;
          -  Women of childbearing potential must be using medically approved methods of birth&#xD;
             control (such as a condom, birth control pill, Depo-Provera, or diaphragm with&#xD;
             spermicides)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Male or female of any race or ethnic origin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime history of bipolar I, psychotic, or cognitive disorders&#xD;
&#xD;
          -  Actively suicidal, homicidal, or psychotic&#xD;
&#xD;
          -  History of sensitivity to divalproex&#xD;
&#xD;
          -  Unstable general medical conditions&#xD;
&#xD;
          -  Score 6 on Question #10 of MADRS&#xD;
&#xD;
          -  Women who are pregnant, planning to become pregnant or to breastfeed during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Lynne Davis, MD AB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuscaloosa VA Medical Center, Tuscaloosa, AL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tuscaloosa VA Medical Center, Tuscaloosa, AL</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 15, 2005</study_first_submitted>
  <study_first_submitted_qc>April 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2005</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticonvulsant</keyword>
  <keyword>anxiety</keyword>
  <keyword>divalproex</keyword>
  <keyword>PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

